Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics, Inc. - Common Stock
(NQ:
STOK
)
31.74
-0.08 (-0.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stoke Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
January 06, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
December 06, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
↗
December 04, 2024
Via
Benzinga
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
↗
June 28, 2024
Via
Benzinga
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
December 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
December 02, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 05, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Analyst Expectations For Stoke Therapeutics's Future
↗
May 06, 2024
Via
Benzinga
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
↗
April 04, 2024
Via
Benzinga
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
September 10, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
September 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
September 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
September 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
↗
June 24, 2024
Via
Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 18, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
June 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 06, 2024
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 06, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
April 29, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
April 04, 2024
Via
Benzinga
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 27, 2024
Via
Benzinga
What's Going On With Stoke Therapeutics Stock Tuesday?
↗
March 26, 2024
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
